| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/10/2005 | WO2005012268A1 Sulfonamide derivative having isoxazole ring |
| 02/10/2005 | WO2005012255A1 Remedy for inflammatory joint diseases |
| 02/10/2005 | WO2005012232A2 Hydrazide derivatives as prostaglandin receptors modulators |
| 02/10/2005 | WO2005011725A2 Anti-angiogenetic agent and its use, in particular in cancer treatment |
| 02/10/2005 | WO2005011721A2 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | WO2005011706A1 2-METHYLENE-19-NOR-20(S)-25-METHYL-1α-HYDROXYCALCIFEROL AND ITS USES |
| 02/10/2005 | WO2005011703A1 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| 02/10/2005 | WO2005011689A2 Treatment of inflamed joints |
| 02/10/2005 | WO2005011669A1 Medicinal composition for percutaneous administration |
| 02/10/2005 | WO2005011402A1 Masticatable capsule and process for producing the same |
| 02/10/2005 | WO2002020718A3 Osteoclast-associated receptor |
| 02/10/2005 | US20050033066 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050033028 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/10/2005 | US20050032929 Maleic anhydride-methyl vinyl ether copolymers; polyamic acids; medical implant device, dressing, scaffold, or fluid adhesive for treatment or prophylaxis of wounds; enhanced activity of protease inhibitors and neurotransmitter drugs |
| 02/10/2005 | US20050032894 Method for manufacturing calcium gluconolcatate compositions, processes and uses |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032865 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 02/10/2005 | US20050032858 Novel heterocyclic compound and anti-inflamatory agent |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032823 analgesics; antipyretics; antiinflammatory agents; antiarthritic agents |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032807 Treatment of cellular tumor growth, tumor proliferation or metastasis using ammonium salts of N delta -acyl derivatives of N alpha (4-amino-4-deoxypteroyl)-L-ornithine compounds |
| 02/10/2005 | US20050032796 Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis |
| 02/10/2005 | US20050032792 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 02/10/2005 | US20050032786 1, 3-benzothiazinone derivatives and use thereof |
| 02/10/2005 | US20050032772 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/10/2005 | US20050032746 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032698 includes a divalent cation (zinc chloride) in an amount effective to stabilize the hormone; osteoporosis |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032685 Remedies for bone loss |
| 02/10/2005 | US20050031709 Butyrospermum-triterpene fraction containing lupeol; alpha -amyrin and/or beta amyrin, and butyrospermol; plant extract |
| 02/10/2005 | US20050031665 Orthopedic hardware with a sustained release device configured to release a compound over an extended period of time and is attachable to a portion of the body |
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | DE10332712A1 Verwendung von c9,t11-Isomeren der konjugierten Linolsäure Use of c9, t11 isomer of conjugated linoleic acid |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2534327A1 Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| 02/10/2005 | CA2532742A1 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | CA2531294A1 2-methylene-19-nor-20(s)-25-methyl-1.alpha.-hydroxycalciferol and its uses |
| 02/10/2005 | CA2529123A1 Hydrazide derivatives as prostaglandin receptors modulators |
| 02/09/2005 | EP1505064A1 2-Aminopyrimidine derivatives |
| 02/09/2005 | EP1504761A1 Difructose anhydride-containing composition and use thereof |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504033A2 Connective tissue stimulating peptides |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503992A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503757A2 Tyrosine kinase inhibitors |
| 02/09/2005 | EP1503752A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1401446B1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 02/09/2005 | EP1385854B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/09/2005 | EP1313885A4 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 02/09/2005 | EP1274980A4 Solution and crystal structures of mmp-13 active site and uses thereof |
| 02/09/2005 | EP1244640B1 Oxazolidinone derivatives |
| 02/09/2005 | EP1200076A4 Calcilytic compounds |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1140939B1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods |
| 02/09/2005 | EP1087951B1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 02/09/2005 | EP1071417B1 Use of cannabidiol as anti-inflammatory agent |
| 02/09/2005 | EP1042316B1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578779A Small organic molecule regulators of cell proliferation |
| 02/09/2005 | CN1578775A 3-amido-1, 2-benzoisoxazole derivatives, process for preparation, and use thereof |
| 02/09/2005 | CN1578773A Methods and compositions of novel triazine compounds |
| 02/09/2005 | CN1578768A Anthranilic acid amides and pharmaceutical use thereof |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1578624A Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability |
| 02/09/2005 | CN1188404C Cyclic compound |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188388C Aminobenzophenones as inhibitors of interleukin and TNF |
| 02/09/2005 | CN1188161C Medicines for treating cervical vertebra illness |
| 02/09/2005 | CN1188152C Chinese medicine composition for treating protrusion of lumber interverterbral disc |
| 02/09/2005 | CN1188147C Bone Bi-syndrome treating pill |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852889 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/08/2005 | US6852863 Osteoporosis; immunosuppressants; wound healing agent |
| 02/08/2005 | US6852839 Fhm, a novel member of the TNF ligand supergene family |
| 02/08/2005 | US6852837 Nucleotide sequences coding protein for use in the treatment nflammatory bowel disease, sepsis, viral diseases and rheumatoid arthritis |
| 02/08/2005 | US6852751 Difluorobutyric acid metalloprotease inhibitors |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852712 Controlling cell differentiation; antiinflammatory agents |